"FIND CAN Trial: CF-172"

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

May 4, 2017

Study Completion Date

August 30, 2017

Conditions
Persistent Atrial Fibrillation
Interventions
DEVICE

Ablation procedure

All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.

All Listed Sponsors
lead

Biosense Webster, Inc.

INDUSTRY

NCT03033641 - "FIND CAN Trial: CF-172" | Biotech Hunter | Biotech Hunter